Mounia Chami

Dr. Mounia Chami

INSERM - Institut National de la Santé et de la Recherche Médicale
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 February 2021 in Autophagy
Verified
Journal Article
Closed access
DKDaniel J. Klionsky
Daniel J. Klionsky
AAAmal Kamal Abdel-Aziz
Amal Kamal Abdel-Aziz
SASara Abdelfatah
Sara Abdelfatah
MAMahmoud Abdellatif
Mahmoud Abdellatif
AAAsghar Abdoli
Asghar Abdoli
CTChun-Kit Tong
Chun-Kit Tong

1 October 2004 in Molecular Cell
Verified
Journal Article
Closed access
GSGyörgy Szabadkai
György Szabadkai
ASAnna Maria Simoni
Anna Maria Simoni
Mounia ChamiMounia Chami
Mounia Chami
MWMariusz Wieckowski
Mariusz Wieckowski
RYRichard J. Youle
Richard J. Youle
RRRosario Rizzuto
Rosario Rizzuto

24 November 2003 in Oncogene
Verified
Journal Article
Closed access
RRRosario Rizzuto
Rosario Rizzuto
PPPaolo Pinton
Paolo Pinton
DFDAVIDE FERRARI
DAVIDE FERRARI
Mounia ChamiMounia Chami
Mounia Chami
GSGyörgy Szabadkai
György Szabadkai
TPTullio Pozzan
Tullio Pozzan

17 June 2003 in Oncogene
Verified
Journal Article
Closed access
PPPatrizia Paterlini-Bréchot
Patrizia Paterlini-Bréchot
KSKenichi Saigo
Kenichi Saigo
YMYoshiki Murakami
Yoshiki Murakami
Mounia ChamiMounia Chami
Mounia Chami
DGDevrim Gozuacik
Devrim Gozuacik
CBChristian Bréchot
Christian Bréchot

3 June 2022 in Molecular Psychiatry
Verified
Journal Article
Open access
PDF file
AMArnaud Mary
Arnaud Mary
FEFanny Eysert
Fanny Eysert
FCFrédéric Checler
Frédéric Checler
Mounia ChamiMounia Chami
Mounia Chami
Mitochondrial dysfunctions are central players in Alzheimer’s disease (AD). In addition, impairments in mitophagy, the process of selective mitochondrial degradation by autophagy leading to a gradual accumulation of defective mitochondria, have also been reported to occur in AD. We provide an updated overview of the recent discoveries and advancements on mitophagic molecular dysfunctions in AD-derived fluids and cells as well as in AD brains. We discuss studies using AD cellular and animal models that have unraveled the contribution of relevant AD-related proteins (Tau, Aβ, APP-derived fragments and APOE) in mitophagy failure. In accordance with the important role of impaired mitophagy in AD, we report on various therapeutic strategies aiming at stimulating mitophagy in AD and we summarize the benefits of these potential therapeutic strategies in human clinical trials.

20 October 2020 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
LVLoan Vaillant-Beuchot
Loan Vaillant-Beuchot
AMArnaud Mary
Arnaud Mary
RPRaphaëlle Pardossi-Piquard
Raphaëlle Pardossi-Piquard
ABAlexandre Bourgeois
Alexandre Bourgeois
ILInger Lauritzen
Inger Lauritzen
Mounia ChamiMounia Chami
Mounia Chami
Several lines of recent evidence indicate that the amyloid precursor protein-derived C-terminal fragments (APP-CTFs) could correspond to an etiological trigger of Alzheimer’s disease (AD) pathology. Altered mitochondrial homeostasis is considered an early event in AD development. However, the specific contribution of APP-CTFs to mitochondrial structure, function, and mitophagy defects remains to be established. Here, we demonstrate in neuroblastoma SH-SY5Y cells expressing either APP Swedish mutations, or the β-secretase-derived APP-CTF fragment (C99) combined with β- and γ-secretase inhibition, that APP-CTFs accumulation independently of Aβ triggers excessive mitochondrial morphology alteration (i.e., size alteration and cristae disorganization) associated with enhanced mitochondrial reactive oxygen species production. APP-CTFs accumulation also elicit basal mitophagy failure illustrated by enhanced conversion of LC3, accumulation of LC3-I and/or LC3-II, non-degradation of SQSTM1/p62, inconsistent Parkin and PINK1 recruitment to mitochondria, enhanced levels of membrane and matrix mitochondrial proteins, and deficient fusion of mitochondria with lysosomes. We confirm the contribution of APP-CTFs accumulation to morphological mitochondria alteration and impaired basal mitophagy in vivo in young 3xTgAD transgenic mice treated with γ-secretase inhibitor as well as in adeno-associated-virus-C99 injected mice. Comparison of aged 2xTgAD and 3xTgAD mice indicates that, besides APP-CTFs, an additional contribution of Aβ to late-stage mitophagy activation occurs. Importantly, we report on mitochondrial accumulation of APP-CTFs in human post-mortem sporadic AD brains correlating with mitophagy failure molecular signature. Since defective mitochondria homeostasis plays a pivotal role in AD pathogenesis, targeting mitochondrial dysfunctions and/or mitophagy by counteracting early APP-CTFs accumulation may represent relevant therapeutic interventions in AD.